請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34998
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊雅雯 | |
dc.contributor.author | Shan-Shan Shen | en |
dc.contributor.author | 沈珊珊 | zh_TW |
dc.date.accessioned | 2021-06-13T06:38:28Z | - |
dc.date.available | 2007-10-03 | |
dc.date.copyright | 2005-10-03 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-08-30 | |
dc.identifier.citation | 1. Audibert, F. M., and L. D. Lise. 1993. Adjuvants: current status, clinical perspectives and future prospects. Trends Pharmacol. Sci. 14:174.
2. Scott, P., and G. Trinchieri. 1997. IL-12 as an adjuvant for cell-mediated immunity. Semin. Immunol. 9:285. 3. Vogel, F. R. 1995. Immunologic adjuvants for modern vaccine formulations. Ann. N. Y. Acad. Sci. 754:153. 4. Rhodes, J., H. Chen, S. R. Hall, J. E. Beesley, D. C. Jenkins, P. Collins, and B. Zheng. 1995. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature 377:71. 5. Gupta, R. K., and G. R. Siber. 1995. Adjuvants for human vaccines--current status, problems and future prospects. Vaccine 13:1263. 6. Iyer, S., R. S. Robinett, H. HogenEsch, and S. L. Hem. 2004. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine 22:1475. 7. Whitehead, M. W., G. Farrar, G. L. Christie, J. A. Blair, R. P. Thompson, and J. J. Powell. 1997. Mechanisms of aluminum absorption in rats. Am. J. Clin. Nutr. 65:1446. 8. Gupta, R. K. 1998. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32:155. 9. Lindblad, E. B. 2004. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82:497. 10. Butz, E. A., and M. J. Bevan. 1998. Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity. 8:167. 11. Kelly, J. M., S. J. Sterry, S. Cose, S. J. Turner, J. Fecondo, S. Rodda, P. J. Fink, and F. R. Carbone. 1993. Identification of conserved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major histocompatibility complex class I-bound determinant. Eur. J. Immunol. 23:3318. 12. Meyer zum Bueschenfelde, C. O., J. Unternaehrer, I. Mellman, and K. Bottomly. 2004. Regulated recruitment of MHC class II and costimulatory molecules to lipid rafts in dendritic cells. J. Immunol. 173:6119. 13. Su, Z., M. F. Tam, D. Jankovic, and M. M. Stevenson. 2003. Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice. Infect. Immun. 71:5178. 14. Mowat, A. M., A. M. Donachie, G. Reid, and O. Jarrett. 1991. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 72:317. 15. Yip, H. C., A. Y. Karulin, M. Tary-Lehmann, M. D. Hesse, H. Radeke, P. S. Heeger, R. P. Trezza, F. P. Heinzel, T. Forsthuber, and P. V. Lehmann. 1999. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162:3942. 16. Robson, N. C., H. Beacock-Sharp, A. M. Donachie, and A. M. Mowat. 2003. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology 109:374. 17. MacKenzie, J. R., J. Mattes, L. A. Dent, and P. S. Foster. 2001. Eosinophils promote allergic disease of the lung by regulating CD4(+) Th2 lymphocyte function. J. Immunol. 167:3146. 18. Liu, L., A. Chahroudi, G. Silvestri, M. E. Wernett, W. J. Kaiser, J. T. Safrit, A. Komoriya, J. D. Altman, B. Z. Packard, and M. B. Feinberg. 2002. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 8:185. 19. Chahroudi, A., G. Silvestri, and M. B. Feinberg. 2003. Measuring T cell-mediated cytotoxicity using fluorogenic caspase substrates. Methods 31:120. 20. Wang, J., O. W. Press, C. G. Lindgren, P. Greenberg, S. Riddell, X. Qian, C. Laugen, A. Raubitschek, S. J. Forman, and M. C. Jensen. 2004. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol. Ther. 9:577. 21. Shresta, S., C. T. Pham, D. A. Thomas, T. A. Graubert, and T. J. Ley. 1998. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10:581. 22. Fortin, A., J. Lagace, and H. M. Therien. 2001. Trafficking of surface-linked and encapsulated liposomal antigens in macrophages: an immunocytochemical study. J. Histochem. Cytochem. 49:1407. 23. Shirota, H., K. Sano, N. Hirasawa, T. Terui, K. Ohuchi, T. Hattori, and G. Tamura. 2002. B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12. J. Immunol. 169:787. 24. Bell, J., and D. Gray. 2003. Antigen-capturing cells can masquerade as memory B cells. J. Exp. Med. 197:1233. 25. Arens, R., M. A. Nolte, K. Tesselaar, B. Heemskerk, K. A. Reedquist, R. A. van Lier, and M. H. van Oers. 2004. Signaling through CD70 regulates B cell activation and IgG production. J. Immunol. 173:3901. 26. Steinman, R. M., and Z. A. Cohn. 1973. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137:1142. 27. Steinman, R. M., D. S. Lustig, and Z. A. Cohn. 1974. Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J. Exp. Med. 139:1431. 28. Ellegaard, J., H. Traunberg, and V. Esmann. 1975. Lymphocyte ATP-ase activity in treated cases of Hodgkin's disease. Scand. J. Haematol. 15:88. 29. Steinman, R. M., and Z. A. Cohn. 1974. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J. Exp. Med. 139:380. 30. Strome, S. E., S. Voss, R. Wilcox, T. L. Wakefield, K. Tamada, D. Flies, A. Chapoval, J. Lu, J. L. Kasperbauer, D. Padley, R. Vile, D. Gastineau, P. Wettstein, and L. Chen. 2002. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 62:1884. 31. Robson, N. C., H. Beacock-Sharp, A. M. Donachie, and A. M. Mowat. 2003. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology 110:95. 32. Araki, N., T. Hatae, A. Furukawa, and J. A. Swanson. 2003. Phosphoinositide-3-kinase-independent contractile activities associated with Fcgamma-receptor-mediated phagocytosis and macropinocytosis in macrophages. J. Cell Sci. 116:247. 33. Rodriguez, A., A. Regnault, M. Kleijmeer, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1:362. 34. Meier, O., K. Boucke, S. V. Hammer, S. Keller, R. P. Stidwill, S. Hemmi, and U. F. Greber. 2002. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J. Cell Biol. 158:1119. 35. Inaba, K., S. Turley, F. Yamaide, T. Iyoda, K. Mahnke, M. Inaba, M. Pack, M. Subklewe, B. Sauter, D. Sheff, M. Albert, N. Bhardwaj, I. Mellman, and R. M. Steinman. 1998. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188:2163. 36. Inaba, K., M. Inaba, M. Naito, and R. M. Steinman. 1993. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J. Exp. Med. 178:479. 37. Oh, Y. K., C. V. Harding, and J. A. Swanson. 1997. The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation. Vaccine 15:511. 38. Marguet, D., M. F. Luciani, A. Moynault, P. Williamson, and G. Chimini. 1999. Engulfment of apoptotic cells involves the redistribution of membrane phosphatidylserine on phagocyte and prey. Nat. Cell Biol. 1:454. 39. Albert, M. L., S. F. Pearce, L. M. Francisco, B. Sauter, P. Roy, R. L. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359. 40. Cherukuri, A., G. Durack, and E. W. Voss, Jr. 1997. Evidence for hapten recognition in receptor-mediated intracellular uptake of a hapten-protein conjugate by murine macrophage. Mol. Immunol. 34:21. 41. Bellette, B. M., G. M. Woods, T. Wozniak, K. V. Doherty, and H. K. Muller. 2003. DEC-205lo Langerinlo neonatal Langerhans' cells preferentially utilize a wortmannin-sensitive, fluid-phase pathway to internalize exogenous antigen. Immunology 110:466. 42. Ota, S., T. Ono, A. Morita, A. Uenaka, M. Harada, and E. Nakayama. 2002. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells. Cancer Res. 62:1471. 43. Klausner, R. D., J. G. Donaldson, and J. Lippincott-Schwartz. 1992. Brefeldin A: insights into the control of membrane traffic and organelle structure. J. Cell Biol. 116:1071. 44. Kovacsovics-Bankowski, M., K. Clark, B. Benacerraf, and K. L. Rock. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. U. S. A 90:4942. 45. Valderrama, F., T. Babia, I. Ayala, J. W. Kok, J. Renau-Piqueras, and G. Egea. 1998. Actin microfilaments are essential for the cytological positioning and morphology of the Golgi complex. Eur. J. Cell Biol. 76:9. 46. Kennedy, R., A. H. Undale, W. C. Kieper, M. S. Block, L. R. Pease, and E. Celis. 2005. Direct cross-priming by th lymphocytes generates memory cytotoxic T cell responses. J. Immunol. 174:3967. 47. Sparwasser, T., E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, and H. Wagner. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:2045. 48. Barreiro, O., M. Yanez-Mo, J. M. Serrador, M. C. Montoya, M. Vicente-Manzanares, R. Tejedor, H. Furthmayr, and F. Sanchez-Madrid. 2002. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J. Cell Biol. 157:1233. 49. Storni, T., T. M. Kundig, G. Senti, and P. Johansen. 2005. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 57:333. 50. HogenEsch, H. 2002. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 Suppl 3:S34-S39. 51. Zinkernagel, R. M., S. Ehl, P. Aichele, S. Oehen, T. Kundig, and H. Hengartner. 1997. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 156:199. 52. Weissburg, R. P., P. W. Berman, J. L. Cleland, D. Eastman, F. Farina, S. Frie, A. Lim, J. Mordenti, T. T. Nguyen, and M. R. Peterson. 1995. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm. Res. 12:1439. 53. Shi, Y., H. HogenEsch, and S. L. Hem. 2001. Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines. Vaccine 20:80. 54. Gupta, R. K., A. C. Chang, P. Griffin, R. Rivera, and G. R. Siber. 1996. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 14:1412. 55. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991. 56. Matzinger, P. 2002. The danger model: a renewed sense of self. Science 296:301. 57. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86. 58. Dupuis, M., T. J. Murphy, D. Higgins, M. Ugozzoli, G. van Nest, G. Ott, and D. M. McDonald. 1998. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 186:18. 59. Iyoda, T., S. Shimoyama, K. Liu, Y. Omatsu, Y. Akiyama, Y. Maeda, K. Takahara, R. M. Steinman, and K. Inaba. 2002. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195:1289. 60. Fukunaga, A., H. Nagai, T. Noguchi, H. Okazawa, T. Matozaki, X. Yu, C. F. Lagenaur, N. Honma, M. Ichihashi, M. Kasuga, C. Nishigori, and T. Horikawa. 2004. Src homology 2 domain-containing protein tyrosine phosphatase substrate 1 regulates the migration of Langerhans cells from the epidermis to draining lymph nodes. J. Immunol. 172:4091. 61. Edinger, A. L., and C. B. Thompson. 2004. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 16:663. 62. Rossi, D., and G. Gaidano. 2003. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 88:212. 63. Alenzi, F. Q., and A. N. Warrens. 2003. Cellular and molecular themes in apoptosis. Wien. Klin. Wochenschr. 115:563. 64. Kerr, J. F., A. H. Wyllie, and A. R. Currie. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239. 65. Walker, N. I., B. V. Harmon, G. C. Gobe, and J. F. Kerr. 1988. Patterns of cell death. Methods Achiev. Exp. Pathol. 13:18. 66. Mitra, R., N. Dharajiya, L. Kumari, C. Varalakshmi, and A. Khar. 2004. Migration of antigen presenting cells from periphery to the peritoneum during an inflammatory response: role of chemokines and cytokines. FASEB J. 18:1764. 67. Nagao, S., and A. Tanaka. 1985. Necrotic inflammatory reaction induced by muramyl dipeptide in guinea pigs sensitized by tubercle bacilli. J. Exp. Med. 162:401. 68. Vermes, I., C. Haanen, and C. Reutelingsperger. 2000. Flow cytometry of apoptotic cell death. J. Immunol. Methods 243:167. 69. Overbeeke, R., H. Steffens-Nakken, I. Vermes, C. Reutelingsperger, and C. Haanen. 1998. Early features of apoptosis detected by four different flow cytometry assays. Apoptosis. 3:115. 70. Vermes, I., C. Haanen, H. Steffens-Nakken, and C. Reutelingsperger. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184:39. 71. Chen, S., C. Rio, R. R. Ji, P. Dikkes, R. E. Coggeshall, C. J. Woolf, and G. Corfas. 2003. Disruption of ErbB receptor signaling in adult non-myelinating Schwann cells causes progressive sensory loss. Nat. Neurosci. 6:1186. 72. Labat-Moleur, F., C. Guillermet, P. Lorimier, C. Robert, S. Lantuejoul, E. Brambilla, and A. Negoescu. 1998. TUNEL apoptotic cell detection in tissue sections: critical evaluation and improvement critical evaluation and improvement. J. Histochem. Cytochem. 46:327. 73. Postier, R. G., M. R. Lerner, S. A. Lightfoot, R. Vannarath, M. M. Lane, J. S. Hanas, and D. J. Brackett. 2003. DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer. J. Histochem. Cytochem. 51:303. 74. Singh, M., and D. O'Hagan. 1999. Advances in vaccine adjuvants. Nat. Biotechnol. 17:1075. 75. Nair, S., F. Zhou, R. Reddy, L. Huang, and B. T. Rouse. 1992. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J. Exp. Med. 175:609. 76. Edelman, R. 1980. Vaccine adjuvants. Rev. Infect. Dis. 2:370. 77. Allison, A. C., and N. E. Byars. 1986. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods 95:157. 78. Ott, G., G. L. Barchfeld, D. Chernoff, R. Radhakrishnan, P. van Hoogevest, and G. Van Nest. 1995. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6:277. 79. Higgins, D. A., J. R. Carlson, and G. Van Nest. 1996. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine 14:478. 80. Ott, G., G. L. Barchfeld, and G. Van Nest. 1995. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13:1557. 81. O'Hagan, D. T., G. S. Ott, and G. Van Nest. 1997. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today 3:69. 82. Kahn, J. O., F. Sinangil, J. Baenziger, N. Murcar, D. Wynne, R. L. Coleman, K. S. Steimer, C. L. Dekker, and D. Chernoff. 1994. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 170:1288. 83. Langenberg, A. G., R. L. Burke, S. F. Adair, R. Sekulovich, M. Tigges, C. L. Dekker, and L. Corey. 1995. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann. Intern. Med. 122:889. 84. Snippe, H., M. J. De Reuver, F. Strickland, J. M. Willers, and R. L. Hunter. 1981. Adjuvant effect of nonionic block polymer surfactants in humoral and cellular immunity. Int. Arch. Allergy Appl. Immunol. 65:390. 85. Hunter, R. L., and B. Bennett. 1984. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 133:3167. 86. Howerton, D. A., R. L. Hunter, H. K. Ziegler, and I. J. Check. 1990. Induction of macrophage Ia expression in vivo by a synthetic block copolymer, L81. J. Immunol. 144:1578. 87. Ragland, W. L., and R. L. Hunter. 2004. Immunomodulation of chickens with the nonionic block polymer T150R1. Immunopharmacol. Immunotoxicol. 26:125. 88. Hunter, R., F. Strickland, and F. Kezdy. 1981. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 127:1244. 89. McNicholl, J. M., K. B. Bond, E. R. Ruhadze, M. R. Olsen, K. Takayama, and R. L. Hunter. 1998. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype. AIDS Res. Hum. Retroviruses 14:1457. 90. Hunter, R. L., and B. Bennett. 1986. The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23:287. 91. Berni, M. G., C. J. Lawrence, and D. Machin. 2002. A review of the rheology of the lamellar phase in surfactant systems. Adv. Colloid Interface Sci. 98:217. 92. Kabanov, A. V., and V. Y. Alakhov. 2002. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev. Ther. Drug Carrier Syst. 19:1. 93. Hanna, N., and K. Hariharan. 1998. Development and application of PROVAX adjuvant formulation for subunit cancer vaccines. Adv. Drug Deliv. Rev. 32:187. 94. Lefevre, T., and M. Subirade. 2003. Formation of intermolecular beta-sheet structures: a phenomenon relevant to protein film structure at oil-water interfaces of emulsions. J. Colloid Interface Sci. 263:59. 95. Vandamme, T. F. 2002. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog. Retin. Eye Res. 21:15. 96. Allison, A. C. 1999. Squalene and squalane emulsions as adjuvants. Methods 19:87. 97. O'Hagan, D. T., M. Singh, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and G. Ott. 2002. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20:3389. 98. Kantaria, S., G. D. Rees, and M. J. Lawrence. 2003. Formulation of electrically conducting microemulsion-based organogels. Int. J. Pharm. 250:65. 99. Woodard, L. F., and R. L. Jasman. 1985. Stable oil-in-water emulsions: preparation and use as vaccine vehicles for lipophilic adjuvants. Vaccine 3:137. 100. Lawrence, M. J., and G. D. Rees. 2000. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45:89. 101. Mei, Z., H. Chen, T. Weng, Y. Yang, and X. Yang. 2003. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur. J. Pharm. Biopharm. 56:189. 102. Homayoun, P., T. Mandal, D. Landry, and H. Komiskey. 2003. Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres. J. Pharm. Pharmacol. 55:933. 103. Kemp, J. M., M. Kajihara, S. Nagahara, A. Sano, M. Brandon, and S. Lofthouse. 2002. Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses. Vaccine 20:1089. 104. Feng, S., and G. Huang. 2001. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control Release 71:53. 105. Alonso, M. J., R. K. Gupta, C. Min, G. R. Siber, and R. Langer. 1994. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 12:299. 106. Puri, N., and P. J. Sinko. 2000. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J. Control Release 69:69. 107. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953. 108. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77. 109. Scheicher, C., M. Mehlig, R. Zecher, and K. Reske. 1992. Dendritic cells from mouse bone marrow: in vitro differentiation using low doses of recombinant granulocyte-macrophage colony-stimulating factor. J. Immunol. Methods 154:253. 110. Rajananthanan, P., G. S. Attard, N. A. Sheikh, and W. J. Morrow. 1999. Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice. Vaccine 18:140. 111. Rafati, H., E. C. Lavelle, A. G. Coombes, S. Stolnik, J. Holland, and S. S. Davis. 1997. The immune response to a model antigen associated with PLG microparticles prepared using different surfactants. Vaccine 15:1888. 112. Agranovich, I., D. E. Scott, D. Terle, K. Lee, and B. Golding. 1999. Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway. Infect. Immun. 67:4418. 113. Bocher, W. O., H. Marcus, R. Shakarchy, B. Dekel, D. Shouval, E. Galun, and Y. Reisner. 1999. Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo. Immunology 96:634. 114. Rajananthanan, P., G. S. Attard, N. A. Sheikh, and W. J. Morrow. 1999. Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses. Vaccine 17:715. 115. Corcoran, A., B. P. Mahon, and S. Doyle. 2004. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1. J. Infect. Dis. 189:1873. 116. Koopman, G., C. P. Reutelingsperger, G. A. Kuijten, R. M. Keehnen, S. T. Pals, and M. H. van Oers. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415. 117. Nicoletti, I., G. Migliorati, M. C. Pagliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139:271. 118. Richardson, T. P., M. C. Peters, A. B. Ennett, and D. J. Mooney. 2001. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19:1029. 119. Qiu, C. H., M. Ohe, N. Koibuchi, and S. Matsuzaki. 2004. Apoptosis in the epididymal epithelium of adult male golden hamster exposed to diethylstilbestrol. J. Histochem. Cytochem. 52:187. 120. Moghaddami, M., B. Swart, P. Reynolds, K. Diener, and M. P. Brown. 2002. Flt3 ligand expands dendritic cell numbers in normal and malignant murine prostate. Immunol. Cell Biol. 80:370. 121. Shin, J. Y., S. K. Lee, C. D. Kang, J. S. Chung, E. Y. Lee, S. Y. Seo, S. Y. Lee, S. Y. Baek, B. S. Kim, J. B. Kim, and S. Yoon. 2003. Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model. Histol. Histopathol. 18:435. 122. Zeng, L., R. G. Rowland, S. M. Lele, and N. Kyprianou. 2004. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum. Pathol. 35:290. 123. Park, J. B. 2003. Phagocytosis induces superoxide formation and apoptosis in macrophages. Exp. Mol. Med. 35:325. 124. Yin, L., Y. Li, J. Ren, H. Kuwahara, and D. Kufe. 2003. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J. Biol. Chem. 278:35458. 125. Kobayashi, S. D., J. M. Voyich, C. L. Buhl, R. M. Stahl, and F. R. DeLeo. 2002. Global changes in gene expression by human polymorphonuclear leukocytes during receptor-mediated phagocytosis: cell fate is regulated at the level of gene expression. Proc. Natl. Acad. Sci. U. S. A 99:6901. 126. Chow, A., D. Toomre, W. Garrett, and I. Mellman. 2002. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 418:988. 127. Dani, A., A. Chaudhry, P. Mukherjee, D. Rajagopal, S. Bhatia, A. George, V. Bal, S. Rath, and S. Mayor. 2004. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment. J. Cell Sci. 117:4219. 128. Muller-Taubenberger, A., A. N. Lupas, H. Li, M. Ecke, E. Simmeth, and G. Gerisch. 2001. Calreticulin and calnexin in the endoplasmic reticulum are important for phagocytosis. EMBO J. 20:6772. 129. Delamarre, L., H. Holcombe, and I. Mellman. 2003. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J. Exp. Med. 198:111. 130. Imai, J., H. Hasegawa, M. Maruya, S. Koyasu, and I. Yahara. 2005. Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. Int. Immunol. 17:45. 131. DiDonato, D., and D. L. Brasaemle. 2003. Fixation methods for the study of lipid droplets by immunofluorescence microscopy. J. Histochem. Cytochem. 51:773. 132. Montero, C. 2003. The antigen-antibody reaction in immunohistochemistry. J. Histochem. Cytochem. 51:1. 133. Sauter, B., M. L. Albert, L. Francisco, M. Larsson, S. Somersan, and N. Bhardwaj. 2000. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191:423. 134. Thumann, P., M. Luftl, I. Moc, M. Bagot, A. Bensussan, G. Schuler, and L. Jenne. 2003. Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy. Br. J. Dermatol. 149:1128. 135. Goldszmid, R. S., J. Idoyaga, A. I. Bravo, R. Steinman, J. Mordoh, and R. Wainstok. 2003. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J. Immunol. 171:5940. 136. Takahashi, M., and Y. Kobayashi. 2003. Cytokine production in association with phagocytosis of apoptotic cells by immature dendritic cells. Cell Immunol. 226:105. 137. Ip, W. K., and Y. L. Lau. 2004. Distinct maturation of, but not migration between, human monocyte-derived dendritic cells upon ingestion of apoptotic cells of early or late phases. J. Immunol. 173:189. 138. Kamath, A. T., J. Pooley, M. A. O'Keeffe, D. Vremec, Y. Zhan, A. M. Lew, A. D'Amico, L. Wu, D. F. Tough, and K. Shortman. 2000. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J. Immunol. 165:6762. 139. Hornell, T. M., G. W. Beresford, A. Bushey, J. M. Boss, and E. D. Mellins. 2003. Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J. Immunol. 171:2374. 140. Montoya, M., G. Schiavoni, F. Mattei, I. Gresser, F. Belardelli, P. Borrow, and D. F. Tough. 2002. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99:3263. 141. Galea-Lauri, J., J. W. Wells, D. Darling, P. Harrison, and F. Farzaneh. 2004. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol. Immunother. 53:963. 142. Storni, T., and M. F. Bachmann. 2004. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J. Immunol. 172:6129. 143. Smith, R. E., A. M. Donachie, D. Grdic, N. Lycke, and A. M. Mowat. 1999. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol. 162:5536. 144. Krishnan, L., S. Sad, G. B. Patel, and G. D. Sprott. 2001. The potent adjuvant activity of archaeosomes correlates to the recruitment and activation of macrophages and dendritic cells in vivo. J. Immunol. 166:1885. 145. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1249. 146. Czerkinsky, C., Z. Moldoveanu, J. Mestecky, L. A. Nilsson, and O. Ouchterlony. 1988. A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J. Immunol. Methods 115:31. 147. Wysocki, L. J., and V. L. Sato. 1978. 'Panning' for lymphocytes: a method for cell selection. Proc. Natl. Acad. Sci. U. S. A 75:2844. 148. Puri, N., and R. K. Saxena. 1998. Induction of proliferation in resting B-cells by a factor released by activated mouse spleen cells. Exp. Mol. Med. 30:199. 149. Yamazaki, S., T. Iyoda, K. Tarbell, K. Olson, K. Velinzon, K. Inaba, and R. M. Steinman. 2003. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198:235. 150. den Haan, J. M., S. M. Lehar, and M. J. Bevan. 2000. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192:1685. 151. Bonifaz, L. C., D. P. Bonnyay, A. Charalambous, D. I. Darguste, S. Fujii, H. Soares, M. K. Brimnes, B. Moltedo, T. M. Moran, and R. M. Steinman. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199:815. 152. Ohl, L., M. Mohaupt, N. Czeloth, G. Hintzen, Z. Kiafard, J. Zwirner, T. Blankenstein, G. Henning, and R. Forster. 2004. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 21:279. 153. O'Neil-Andersen, N. J., and D. A. Lawrence. 2002. Differential modulation of surface and intracellular protein expression by T cells after stimulation in the presence of monensin or brefeldin A. Clin. Diagn. Lab Immunol. 9:243. 154. O I, M. Blaszczyk-Thurin, C. T. Shen, and H. C. Ertl. 2003. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther. 10:678. 155. Doody, A. D., J. T. Kovalchin, M. A. Mihalyo, A. T. Hagymasi, C. G. Drake, and A. J. Adler. 2004. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34998 | - |
dc.description.abstract | 抗原本身所引起的免疫原性較弱,加入適當的佐劑可以加強抗原之免疫原性和免疫保護的效果。從七十多年前在疫苗研製過程中開始使用免疫佐劑,其中以氫氧化鋁和磷酸鋁為代表的鋁礬 (alum) 至今仍是唯一被批准合法使用在人體的疫苗佐劑,因此佐劑的開發是值得研究的課題。本論文利用非離子性界面活性劑 (non-ionic surfactants),包括 Tweens (polyoxyethylene sorbitans) 及 Spans (sorbitans),製作出六種具不同 HLB (hydrophile-lipophile balance) 值與不同物化性質的乳劑型疫苗佐劑,以探討其造成疫苗免疫效應之機轉研究。
為了探討所製作出的乳劑型疫苗佐劑之物化性質,我們分析乳劑的電導度、黏度與蛋白質從佐劑中釋出的速率。為了要觀察六種不同乳劑型疫苗佐劑所引起的免疫反應,我們以 ovalbumin (OVA) 當作抗原,將抗原與乳劑型疫苗佐劑混合後打入雄性 C57BL/6J 小鼠,於不同時間點收集血清測量 anti-OVA 的效價 (titer) 與 IgG subtyping。為了觀察乳劑型疫苗佐劑是否會引起細胞死亡,我們分別在活體外用 EL4 細胞來觀察,並以 annexin V/propidium iodide 雙染色。我們同時也在活體內將小鼠注射部位組織取下來切片,以 H&E (hematoxylin & eosin)、TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick-end labeling) 兩種方法染色,觀察乳劑型疫苗佐劑在活體內所引起之發炎反應與細胞死亡。 為了探討佐劑與死亡細胞對抗原呈獻細胞吞噬抗原的影響,我們利用小鼠的巨噬細胞株 J774A.1 當作抗原呈獻細胞來進行細胞實驗,並以 BSA-FITC 及 OVA 當作抗原。為了探討抗原呈獻細胞吞噬佐劑之抗原的機轉,我們加入三種抑制劑來觀察,其中 amiloride 可抑制 macropinocytosis、brefeldin A 可抑制 endocytosis、cytochalasin B 可抑制 phagocytosis。同時我們以 2',7'-dichlorofluorescin diacetate (DCFH-DA) 與 hydroethidine (HE) 探測乳劑型疫苗佐劑是否會產生活性氧物系以及氧化壓力。為了探討佐劑所含抗原在抗原呈獻細胞內處理的過程,我們將 J774A.1 細胞分別染上不同胞器來觀察。 由於佐劑所造成的細胞死亡在疫苗引起之免疫反應上扮演一個重要的角色,因此我們將佐劑處理過的 EL4 細胞與樹突狀細胞共同培養,以探討樹突狀細胞吞噬死亡細胞的情形;另外,也一併探討樹突狀細胞吞噬死亡細胞後,樹突狀細胞表面共刺激分子 (costimulatory molecules),包括 MHC class II、CD40、CD80、CD86 的表現情形為何,來觀察樹突狀細胞是否進入成熟期。 樹突狀細胞在未成熟期可吞噬抗原,吞噬抗原後則進入成熟期,成熟期的樹突狀細胞可將抗原呈獻給下游的淋巴細胞。為了分析打入乳劑型疫苗佐劑後對小鼠淋巴結細胞的影響,我們首先將注射七天後的小鼠淋巴結取出,再用 methyl-[3H] thymidine 標定,以觀察淋巴結 T 細胞的增生情形;同時以 ELISPOT (enzyme-linked immunospot) 的方法來觀察經乳劑型疫苗佐劑處理後的小鼠淋巴結 B 細胞是否會產生 OVA 專一性抗體。 為了探討乳劑型疫苗佐劑是否會引起細胞免疫反應 (cell-mediated immune responses),我們利用毒殺細胞毒殺標的細胞時會產生 granzyme B 的原理來觀察小鼠脾臟 T 細胞的細胞毒殺情形。同時也利用一種會對 OVA 引起 MHC class I 反應的 B3Z T 細胞,在活體外觀察乳劑型疫苗佐劑是否會引起細胞免疫。 由實驗結果發現,當佐劑黏度愈大時、蛋白質愈不容易自佐劑中釋出,但所製作出不同物化性質的佐劑在動物體所產生的 anti-OVA 效價並無明顯差異,且主要是引起 IgG1 subtype 的產生。乳劑型疫苗佐劑會在注射部位同時引起發炎反應及細胞死亡的情形,在體外也可以同時引起細胞凋亡與細胞壞死,且佐劑所造成的死亡細胞可被樹突狀細胞吞噬,並造成樹突狀細胞成熟。佐劑與死亡細胞可以增加 J774A.1 細胞吞噬抗原的量,吞噬抗原後會經由 lysosome、endothelium reticulum (ER)、Golgi apparatus、MHC class II 等胞器將抗原分解成胜肽片段,而吞噬抗原的步驟會被 amiloride、brefeldin A 及 cytochalasin B 等抑制劑所抑制。佐劑與死亡細胞也會造成 J774A.1 細胞產生活性氧化物以及產生氧化壓力。打入乳劑型疫苗佐劑會造成小鼠淋巴結 T 細胞增生,並造成淋巴結 B 細胞產生 OVA 專一性抗體。在脾臟細胞的細胞毒殺試驗中,除了 L121-adj. 外,其他乳劑型疫苗佐劑並無產生明顯的細胞毒殺作用,在體外實驗中,也沒有造成 B3Z T 細胞的活化。 總而言之,本研究證實了乳劑型疫苗佐劑會同時造成細胞凋亡與細胞壞死、且可增加抗原被抗原呈獻細胞所吞噬。抗原經由 macropinocytosis、phagocytosis 等方式進入抗原呈獻細胞後,會經由 lysosome、ER、Golgi apparatus、MHC class II 分解成胜肽片段。佐劑同時也會造成樹突狀細胞成熟,進而將抗原傳遞給下游的 T 細胞與 B 細胞,造成 T 細胞的增生,並使 B 細胞產生抗原專一性的抗體免疫反應。除了 L121-adj. 外,含 Tweens 與 Spans 之乳劑型疫苗佐劑並不會引起顯著的細胞免疫反應 (cell-mediated immune responses)。 | zh_TW |
dc.description.abstract | Adjuvants are used to improve the immune response to weak vaccine antigens. Aluminum adjuvant has used in human and veterinary vaccines for over seventy years, and it is the only adjuvant used in human. The development of new vaccine adjuvants is crucial. In the present study, emulsion vaccine adjuvants containing the non-ionic surfactants, including Tweens (polyoxyethylene sorbitan fatty acid esters) and Spans (sorbitan fatty acid esters) with various HLB (hydrophile-lipophile balance) values were prepared and used for studying the immunogenic mechanisms of emulsion vaccine adjuvants.
The emulsion adjuvants were prepared by mixing squalane, PBS and 2% (w/w) surfactants, and their physicochemical properties, including conductivity, viscosity, and protein release rates were determined. To examine the immunogenic response, C57BL/6J mice were immunized with various vaccine adjuvants employing ovalbumin (OVA) as a model antigen. The blood samples were collected periodically and analyzed by enzyme-linked immunosorbent assay (ELISA). To examine cell death induced by the emulsion adjuvants in vitro, EL4 cells were treated with various formulations, stained with annexin V and propidium iodide, followed by flow cytometric analysis. Cell death induced by the adjuvants in vivo was examined by histochemical staining of the subcutaneous tissues at the injection sites, followed by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP- digoxigenin nick-end labeling) assay. To investigate the effect of adjuvants on the uptake of antigen and the adjuvant-induced dead cells, murine macrophages J774A.1 cells were pretreated with macropinocytosis and phagocytosis inhibitors, including amiloride, brefeldin A and cytochalasin B, and pulsed with adjuvants containing the adjuvant-induced dead cells, followed by flow cytometric analysis and fluorescence microscopic examination. The production of reactive oxygen species (ROS) in the cells after treatment with the emulsion vaccine adjuvants was also determined. To examine antigen processing in the antigen-presenting cells, J774A.1 cells were stained with different fluorescent organelle markers, including LAMP1, cathepsin D, MHC class II, calnexin and GM130 antibodies, and examined by fluorescence microscope. Adjuvant-induced cell death plays an important role in the initiation of immune responses. To investigate phagocytosis of adjuvant-induced dead cells by dendritic cells, the most powerful antigen-presenting cells, adjuvant-treated EL4 cells were co-cultured with dendritic cells for 6 hours. The effect of cell death induced by the adjuvants on the expressions of costimulatory molecules of DCs, including MHC class II, CD40, CD80 and CD86, was examined by flow cytometry. To investigate the immune response induced by the emulsion vaccine adjuvants, cells in the draining lymph nodes near the injection sites were removed after immunization and analyzed by flow cytometry. To examine the effect of adjuvants on T cell proliferation in the draining lymph nodes, lymphocytes were labeled with methyl-[3H] thymidine, and the radioactivity was determined by a β-counter. The OVA-specific antibody response of B cells in the lymph nodes after immunization with various adjuvants was examined by enzyme-linked immunospot (ELISPOT) assay. To investigate cell-mediated immune responses induced by the emulsion vaccine adjuvants, splenocytes were examined at Day 10 after immunization, and the cytotoxicity assay was performed by measurement of the granzyme B activity. Primed DCs were assessed by the in vitro activation of B3Z OVA-specific CD8+ T cells. Results obtained in this study showed that protein release from emulsion vaccine adjuvants decreased with the viscosity of the emulsions. The anti-OVA titers in the animals immunized with the emulsion vaccine adjuvants were approximately the same among six emulsion adjuvants, with IgG1 subtype being dominant, suggesting a type II immune response. Emulsion vaccine adjuvants induced inflammation and cell death, including apoptosis and necrosis, both in vitro and in vivo. Adjuvant-induced dead cells were phagocytosed by the dendritic cells, and stimulated the expression of costimulatory molecules, including CD40, CD80, and CD86. Uptake of dead cells induced by the adjuvants enhanced uptake of soluble antigens by J774A.1 macrophages, leading to generation of reactive oxygen species (ROS). The acquired antigen was processed through lysosome, endothelium reticulum (ER), Golgi apparatus, and MHC class II, the antigen uptake was inhibited by amiloride, brefeldin A, and cytochalasin B. Emulsion vaccine adjuvants were shown to induce T cell proliferation and production of OVA-specific B cells in the draining lymph nodes. However, most emulsion vaccine adjuvants, except L121-adjuvant, did not induce significant CTL effect or B3Z OVA-specific T cell activation. In summary, we have demonstrated in this study that emulsion vaccine adjuvants stimulated humoral responses and induced cell death, resulting in inflammation at the injection sites of the animals. The antigen-presenting cells acquired antigen by macropinocytosis and phagocytosis, and the antigens were processed through lysosome, ER, Golgi apparatus, and loaded onto MHC class II molecules. The uptake of antigens by the antigen-presenting cells can be partially inhibited by amiloride, brefeldin A and cytochalasin B. The emulsion vaccine adjuvants induced antigen-specific T cell proliferation and B cell response in the draining lymph nodes. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T06:38:28Z (GMT). No. of bitstreams: 1 ntu-94-R91423021-1.pdf: 3050552 bytes, checksum: 089eaf6cadfee7588a817cad01b16edf (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 中文摘要 i
Abstract iv 壹、文獻回顧 1 一、免疫反應 (immunity) 1 二、抗原呈獻細胞 (antigen-presenting cells) 2 三、疫苗佐劑的功能 (adjuvant functions) 4 四、乳劑型疫苗佐劑(emulsion vaccine adjuvants) 6 貳、研究動機目的與實驗設計 8 參、材料與方法 10 第一部分、材料與疫苗佐劑的製備 10 一、材料 10 二、L121 佐劑 (L121-adj.) 的製備 10 三、乳劑型疫苗佐劑的製備 10 第二部分、疫苗佐劑的物化性質 10 一、傳導性試驗 11 二、黏度試驗 11 三、佐劑與 OVA 蛋白質親和力試驗 11 第三部分、細胞培養 12 第四部份、活體內、外免疫反應與抗原呈獻細胞實驗 12 一、酵素聯結免疫吸附法 (ELISA) 12 二、活體外細胞凋亡/細胞壞死情形 (AnnV/PI) 14 三、活體內細胞發炎情形 (H&E staining) 14 四、活體內細胞凋亡/細胞壞死情形 (TUNEL assay) 15 第五部分、細胞實驗 16 一、巨噬細胞吞噬抗原試驗 16 二、活性氧物系 (Reactive Oxygen Species; ROS) 之分析 16 三、抗原呈獻細胞胞器處理抗原試驗 18 四、樹突狀細胞吞噬抗原試驗 18 五、樹突狀細胞表面 CD marker 表現 19 第六部分、活體淋巴細胞實驗 19 一、C57BL/6J 小鼠淋巴結之細胞分析 19 二、淋巴結 T 細胞增生試驗 19 三、淋巴結 B 細胞表現抗體情形 20 四、打入高濃度抗原分析淋巴結細胞吞噬抗原實驗 20 五、分離 B 細胞與 T 細胞 (B cell panning) 21 六、脾臟細胞毒殺性試驗 (CTL) 21 七、B3Z T 細胞活化實驗 23 第七部份、數據分析 23 肆、結果 24 第一部分、乳劑型疫苗佐劑的物化性質分析 24 一、利用電導度試驗決定乳劑型疫苗佐劑的型態 24 二、w/o 型乳劑的黏度較高,o/w 型乳劑的黏度較低 24 三、乳劑型疫苗佐劑內的蛋白質釋出速率與其黏度呈反比 25 第二部分、乳劑型疫苗佐劑在動物體內外所引起免疫反應的探討 25 一、乳劑型疫苗佐劑引起對 OVA 的效價相似,並未因抗原放速率不同而有所不同 25 二、乳劑型疫苗佐劑會同時引起活體外的細胞凋亡與細胞壞死 26 三、乳劑型疫苗佐劑會引起注射部位細胞發炎及細胞凋亡/細胞壞死的情形 26 第三部份、細胞實驗 27 一、加入處理過的EL4細胞會增加吞噬抗原的量,同時吞噬抗原的量會受到抑制劑的抑制 27 二、乳劑型佐劑會產生 ROS (reactive oxygen species) 而造成細胞壓力 28 三、乳劑型疫苗佐劑所含的抗原會經由抗原呈獻細胞的胞器處理 29 第四部分、抗原呈獻細胞可吞噬佐劑誘發的死亡細胞,而使抗原呈獻細胞成熟 29 一、樹突狀細胞可以吞噬死亡細胞 29 三、吞噬死亡細胞後樹突狀細胞會被活化 30 第五部份、淋巴細胞之實驗結果 30 一、 C57BL/6J 小鼠淋巴結之細胞分析 30 二、 C57BL/6J 小鼠淋巴結之 T 細胞增生的情形 31 三、 C57BL/6J 小鼠淋巴結 B 細胞產生抗體的情形 31 四、細胞毒殺試驗 32 五、B3Z T 細胞活化實驗 32 六、小鼠淋巴結吞噬高濃度抗原實驗 33 伍、討論 34 第一部分:關於乳劑型疫苗佐劑的物化性質與抗原呈獻細胞之作用 34 第二部分:關於乳劑型疫苗佐劑對淋巴細胞之影響 37 陸、結論 39 柒、參考資料 40 捌、圖表 53 | |
dc.language.iso | zh-TW | |
dc.title | 乳劑型疫苗佐劑之免疫機轉研究 | zh_TW |
dc.title | Studies on the immune mechanisms of emulsion vaccine adjuvants | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 伍安怡,繆希椿 | |
dc.subject.keyword | 疫苗,佐劑,乳劑, | zh_TW |
dc.subject.keyword | vaccine,adjuvant,emulsion, | en |
dc.relation.page | 85 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2005-08-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 2.98 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。